ALYFTREK®

Drug Information Related Patent

Hold Company

VERTEX PHARMS INC

Learn More

Dosage and Administration

TABLET;ORAL

Specification

50MG 20MG EQ 4MG BASE; 125MG 50MG EQ 10MG BASE

Indication

Alyftrek® is indicated for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

Use

Instructions for Use

API

DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM

API Structure

We Supply

TEZACAFTOR

Drug Patent

Patent No	Expiration Date
10022352	2027/4/9
10047053	2032/5/17
10081621	2031/3/25
10239867	2027/4/9
10646481	2029/8/13
11066417	2039/2/14
11564916	2029/8/13
11578062	2031/3/25
11639347	2027/4/9
11866450	2039/2/14
11873300	2040/8/13
7495103	2027/5/20
7645789	2027/5/1
7776905	2027/6/3
8324242	2027/8/5
8354427	2026/7/6
8410274	2026/12/28
8415387	2027/11/12
8598181	2027/5/1
8623905	2027/5/1
8629162	2025/6/24
8754224	2026/12/28
8865902	2032/5/17
9181192	2032/5/17
9512079	2032/5/17
9670163	2026/12/28
9931334	2026/12/28
9974781	2027/4/9

API Patent

Patent No	Expiration Date
10022352	2027/4/9
10047053	2032/5/17
10239867	2027/4/9
11066417	2039/2/14
11639347	2027/4/9
11866450	2039/2/14
7495103	2027/5/20
7645789	2027/5/1
7776905	2027/6/3
8324242	2027/8/5
8354427	2026/7/6
8415387	2027/11/12
8598181	2027/5/1
8623905	2027/5/1
8865902	2032/5/17
9181192	2032/5/17
9512079	2032/5/17
9974781	2027/4/9

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.